Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
Minnesota lawmakers vote 114-15 to legalize regulated psilocybin-assisted therapy, making the state the fourth in the nation to authorize supervised psychedelic treatment for mental health and substance use disorders.
University of Alabama at Birmingham study published in JAMA Network Open finds psilocybin-assisted therapy significantly improved abstinence rates among individuals with cocaine use disorder, offering hope for a condition with no FDA-approved medications.
Flow Neuroscience's tDCS device becomes the first FDA-approved at-home brain stimulation treatment for depression, potentially transforming access to care for millions and offering hope for co-occurring substance use disorders.
Mississippi secures $40.9 million from $7.4 billion Purdue-Sackler settlement, bringing total opioid recovery to over $400 million for addiction treatment and prevention programs.
Mayor Mamdani directs opioid settlement funds to create 500 peer specialist positions, expanding community-based addiction treatment and outreach across all five boroughs.
US authorities issue urgent warning to international visitors ahead of 2026 FIFA World Cup about fentanyl contamination in street drugs, as DEA reports 29% of seized pills contain lethal doses.
New NIH-funded research reveals that oral small-molecule GLP-1 drugs like orforglipron suppress hedonic feeding by modulating the central amygdala, opening potential pathways for treating substance use disorders.
White House releases ambitious 195-page drug control strategy calling for easier treatment access, but administration's funding cuts and policy shifts threaten implementation.
Maryland's highest court rejects 'public nuisance' theory in opioid litigation, forcing Baltimore to dismiss case against McKesson and Cencora while keeping $400 million in earlier settlements.